BR112022022089A2 - HETERODIMERIC PROTEIN COMPOSITION, THERAPEUTIC COMPOSITION COMPRISING THE SAME AND USE OF SAID COMPOSITION TO TREAT A DISEASE ASSOCIATED WITH IL-1SS MODULATION - Google Patents
HETERODIMERIC PROTEIN COMPOSITION, THERAPEUTIC COMPOSITION COMPRISING THE SAME AND USE OF SAID COMPOSITION TO TREAT A DISEASE ASSOCIATED WITH IL-1SS MODULATIONInfo
- Publication number
- BR112022022089A2 BR112022022089A2 BR112022022089A BR112022022089A BR112022022089A2 BR 112022022089 A2 BR112022022089 A2 BR 112022022089A2 BR 112022022089 A BR112022022089 A BR 112022022089A BR 112022022089 A BR112022022089 A BR 112022022089A BR 112022022089 A2 BR112022022089 A2 BR 112022022089A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- heterodimeric protein
- human
- modulation
- treat
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000035772 mutation Effects 0.000 abstract 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 abstract 2
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 abstract 2
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 abstract 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 abstract 1
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000539 dimer Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000833 heterodimer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
INIBIDOR DE IL-1ß, DERIVADO DE IL1-R1 E A APLICAÇÃO DO MESMO. A composição terapêutica descrita pode ser usada para tratar ou prevenir doenças associadas à modulação da atividade da IL-1ß humana. Em certos aspetos, a composição revelada é baseada na engenharia da estrutura de uma proteína heterodimérica capaz de se ligar à IL-1ß humana e enfraquecer a função da mesma. A estrutura da proteína heterodimérica inclui os locais extracelulares de IL1-R1 e IL- 1RAcP humanas ou os seus fragmentos funcionais. Cada uma delas, uma parte de IL1-R1 e uma parte de IL-1RAcP ligam-se a uma mutação separada de Fc-segmento da Ig Gamma-1 humana. Duas mutações separadas de Fc na estrutura da proteína heterodimérica são compostas de modo a contribuir à formação de um dímero heterodímero entre duas mutações de Fc em vez de qualquer estrutura homomérica. A composição terapêutica destina-se para o uso no tratamento das pessoas e dos animais.IL-1ß INHIBITOR, IL1-R1 DERIVATIVE AND THE APPLICATION OF THE SAME. The described therapeutic composition can be used to treat or prevent diseases associated with modulation of human IL-1ß activity. In certain aspects, the disclosed composition is based on engineering the structure of a heterodimeric protein capable of binding human IL-1ß and impairing its function. The structure of the heterodimeric protein includes the extracellular sites of human IL1-R1 and IL-1RAcP or their functional fragments. Each part of IL1-R1 and part of IL-1RAcP bind to a separate Fc-segment mutation of human Ig Gamma-1. Two separate Fc mutations in the heterodimeric protein structure are compounded so as to contribute to the formation of a heterodimer dimer between two Fc mutations rather than any homomeric structure. The therapeutic composition is intended for use in the treatment of people and animals.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2020/034114 WO2021236091A1 (en) | 2020-05-22 | 2020-05-22 | Il1-r1 derived inhibitor of il-1b and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022089A2 true BR112022022089A2 (en) | 2022-12-13 |
Family
ID=78708753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022089A BR112022022089A2 (en) | 2020-05-22 | 2020-05-22 | HETERODIMERIC PROTEIN COMPOSITION, THERAPEUTIC COMPOSITION COMPRISING THE SAME AND USE OF SAID COMPOSITION TO TREAT A DISEASE ASSOCIATED WITH IL-1SS MODULATION |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4153613A4 (en) |
| JP (1) | JP2023527171A (en) |
| CN (1) | CN115768787A (en) |
| BR (1) | BR112022022089A2 (en) |
| MX (1) | MX2022014410A (en) |
| WO (1) | WO2021236091A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1016673B1 (en) * | 1992-10-02 | 2006-02-01 | Genetics Institute, LLC | Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer |
| AU2013378122B2 (en) * | 2013-02-15 | 2019-05-02 | R-Pharm International, Limited Liability Company | IL-1beta inhibitor composition and use thereof |
| US11155600B2 (en) * | 2014-03-24 | 2021-10-26 | R-Pharm Overseas, Inc. | Human IL1-R1 derived inhibitor of IL-1β |
-
2020
- 2020-05-22 MX MX2022014410A patent/MX2022014410A/en unknown
- 2020-05-22 BR BR112022022089A patent/BR112022022089A2/en unknown
- 2020-05-22 EP EP20936359.7A patent/EP4153613A4/en active Pending
- 2020-05-22 JP JP2022571138A patent/JP2023527171A/en active Pending
- 2020-05-22 WO PCT/US2020/034114 patent/WO2021236091A1/en active Application Filing
- 2020-05-22 CN CN202080101065.9A patent/CN115768787A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022014410A (en) | 2022-12-06 |
| EP4153613A4 (en) | 2024-01-24 |
| CN115768787A (en) | 2023-03-07 |
| JP2023527171A (en) | 2023-06-27 |
| WO2021236091A1 (en) | 2021-11-25 |
| EP4153613A1 (en) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sanford et al. | Lightning and thermal injuries | |
| BRPI0502691A (en) | pharmaceutical composition for the control of blood glucose in patients with type 2 diabetes | |
| BR112015019729A2 (en) | il-1b inhibitory composition and use thereof | |
| Ordahan et al. | Efficacy of paraffin wax bath for carpal tunnel syndrome: a randomized comparative study | |
| Soyupek et al. | The efficacy of phonophoresis on electrophysiological studies of the patients with carpal tunnel syndrome | |
| BR112022022089A2 (en) | HETERODIMERIC PROTEIN COMPOSITION, THERAPEUTIC COMPOSITION COMPRISING THE SAME AND USE OF SAID COMPOSITION TO TREAT A DISEASE ASSOCIATED WITH IL-1SS MODULATION | |
| Ciuciulete et al. | Non-melanoma skin cancer: statistical associations between clinical parameters | |
| Nizhu et al. | High-voltage electrocution-induced pulmonary injury and cerebellar hemorrhage with fractures in atlas | |
| Mahrer et al. | Atropine-like poisoning due to tranquilizing agents | |
| Malik et al. | Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy | |
| BR112022010227A2 (en) | LONG-ACTING GDF15 FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| Veal et al. | Hyperhidrosis: observations on the study of sixty-one cases | |
| Lewkonia et al. | Granulomatous vasculitis in the syndrome of diffuse fasciitis with eosinophilia | |
| Stone | Sulfapyride and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum | |
| M Gallo et al. | Effect of massage by using lavender and chamomile oils of intact skin on outcomes of moderately burned patients | |
| Vuopala et al. | Dimethyl Sulfoxide (DMSO) Ointment in the Treatment of Rheumatoid Arthritis: A Double Blind Study | |
| ROWNTREE et al. | Polyarthritis: Further studies on the effects of sympathetic ganglionectomy and ramisectomy | |
| Lankani et al. | Effect of Sri Lankan traditional medicine Jathiphalaadi Lepa and Heen Demata Yusha Nasya on Manibandha Shoola [Carpal Tunnel Syndrome]-A Case Report | |
| Katz et al. | The use of topical thiabendazole in dimethylsulfoxide for creeping eruption: preliminary report | |
| Nalawade et al. | COMPREHENSIVE REVIEW OF SCORPION ENVENOMATION: BIOLOGY, CLINICAL MANIFESTATIONS, AND MANAGEMENT STRATEGIES IN SOUTH INDIA | |
| Sengupta et al. | Panchakarma management of Abhighataja Pakshaghata (Traumatic Hemiplegia)-A case study | |
| Lowe et al. | Cold sensitivity as a new side effect after sympathicotomy for hyperhidrosis | |
| Tekam et al. | A conceptual study on Marma and its practical application in Chikitsa | |
| Rowe et al. | Allergic Dermatitis: Report of a Case Due to Mohair | |
| Saffan et al. | Comparison of the effectiveness of low level laser therapy plus exercises and phonophoresis plus exercises in treatment of idiopathic carpal tunnel syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |